A Study to Investigate the Safety and Effect of Food on the Pharmacokinetics of YM178 in Healthy Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-03-31

Study Completion Date

2011-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to evaluate safety of YM178 and the effect of food intake on the pharmacokinetics of YM178 in healthy adult subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Investigate the Effect of Food With Mirabegron in Healthy Chinese Participants

NCT04501640

Pharmacokinetics of Mirabegron Food Effect Healthy Chinese Subjects

COMPLETED PHASE4

Study to Assess the Safety and Plasma Concentration of YM178 OCAS Tablet (Mirabegron) in Healthy Chinese Volunteers

NCT01720212

Healthy Chinese Volunteers

COMPLETED PHASE1

A Study of Safety, Pharmacokinetics (Including Food Effect) And Pharmacodynamics of RO5545965 in Healthy Volunteers

NCT01711801

Healthy Volunteer

COMPLETED PHASE1

A Food-Effect Study of AND017 in Healthy Participants

NCT04712500

Healthy Volunteers

COMPLETED PHASE1

Evaluation Of The Potential Effect That The Administration Of Food Or Antacid Medication May Have In The Oral Absorption Of Dacomitinib (PF-00299804)

NCT01702506

Healthy Volunteers

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A open-label, randomized, crossover study to assess the effect of food on the pharmacokinetics of single dose of YM178 administered under fasted and fed conditions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteer Pharmacokinetics of YM178

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part A group

fasted condition then fed condition

Group Type EXPERIMENTAL

YM178

Intervention Type DRUG

oral

Part B group

fed condition then fasted condition

Group Type EXPERIMENTAL

YM178

Intervention Type DRUG

oral

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

YM178

oral

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

mirabegron

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* A normal or clinically non-significant 12 lead ECG as well as normal or clinically non-significant laboratory test results at the time of Screening
* Body weigh at least 50 kg in male and 45 kg in female and body mass index (BMI) between 18.5 and 26.9 kg/m2
* All women of child bearing potential are required to use adequate contraception consisting of two forms of birth control

Exclusion Criteria

* Hypersensitivity to YM178 or other beta-3 agonists or any of the constituents of the formulation used
* Liver function test values above the upper limit of normal
* A history or presence of psychiatric illness, serious active or recurrent infection
* A previous history of cancer other than basal cell carcinoma or Stage 1 squamous cell carcinoma that has not been in remission for at least 5 years prior to the study
* Donated or lost ≥ 500 mL blood within 3 months or donated plasma within 2 weeks prior to the study
* Receiving or being anticipated to receive a prescription drug or OTC medications within 14 days prior to the study
* Consuming alcohol, xanthine derivative-containing food/beverages (tea, chocolate), grapefruit juice, grapefruit-containing products or Seville oranges (e.g., bitter marmalade) within 48 hours before the study
* A history of substance abuse, drug addiction, or alcoholism within past 2 years prior to the study
* currently participating in another clinical trial or taking or has been taking an investigational drug at least 60 days

Minimum Eligible Age

20 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes